Cyclacel Pharma (CYCC) Tops Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts CYCC Hot Sheet
Price: $6.37 --0%
Financial Fact:
Foreign exchange (losses)/gains: 51K
Today's EPS Names:
PFBX, GOVB, VABK, More
Financial Fact:
Foreign exchange (losses)/gains: 51K
Today's EPS Names:
PFBX, GOVB, VABK, More
Join SI Premium – FREE
Cyclacel Pharma (NASDAQ: CYCC) reported Q4 EPS of ($0.20), $0.06 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $299 thousand, versus $247 thousand reported last year.
Cyclacel reported Q413 loss of $0.21 per share.
For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SPS Commerce (SPSC) Tops Q3 EPS by 16c; Offers Guidance
- Portland General Electric (POR) Misses Q3 EPS by 13c; lowers guidance
- Minerals Technologies (MTX) Tops Q3 EPS by 2c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
